Immunotherapy Timing for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines whether the timing of immunotherapy treatment affects its effectiveness for individuals with advanced lung cancer or other solid tumors. Participants will receive a PD-1 blocker, a type of immunotherapy, either in the morning or afternoon to determine if timing influences treatment outcomes. Individuals with advanced lung cancer or solid tumors who have not yet received immunotherapy, or who qualify for maintenance therapy, may be suitable candidates. Participants must be willing to receive treatment at a specific time of day and meet certain medical criteria. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant findings.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that this trial's treatment is likely to be safe?
Research has shown that PD-1 blockers are generally safe and effective for treating advanced lung cancer. Studies have found that treatments like pembrolizumab and nivolumab can extend patients' lives and shrink tumors. In these studies, patients typically experienced manageable side effects. Some individuals did encounter immune-related side effects, but these were often mild or moderate. The FDA has already approved these treatments for similar conditions, indicating a strong safety record.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it explores the timing of immunotherapy doses, which may impact their effectiveness against lung cancer. Most treatments for lung cancer, like chemotherapy, work by killing fast-growing cells, but this study examines the potential benefits of administering a PD-1 blocker, a type of immunotherapy, at different times of the day. By comparing early morning doses to afternoon doses, researchers hope to discover if the body's biological clock can influence the treatment's success. This could lead to more personalized treatment schedules, potentially improving patient outcomes.
What evidence suggests that this trial's treatments could be effective for lung cancer?
Research has shown that PD-1 blockers, like pembrolizumab, effectively treat non-small cell lung cancer (NSCLC). These treatments can extend patients' lives by inhibiting cancer cell growth. In this trial, participants will be assigned to different arms based on the timing of their treatment. Some will receive early immunotherapy dosing, while others will receive late immunotherapy dosing. Some studies suggest that earlier treatment in the day might enhance effectiveness. Specifically, patients treated earlier demonstrated better outcomes than those treated later. This suggests that both the treatment and its timing can be crucial for achieving the best results.46789
Who Is on the Research Team?
Liza Villaruz, MD
Principal Investigator
UPMC Hillman Cancer Center
Are You a Good Fit for This Trial?
This trial is open to patients with any advanced or metastatic cancer where first-line anti-PD-1/PD-L1 immunotherapy is an approved treatment. Participants will be randomly assigned to receive their treatments either in the morning (before 11:00 AM) or in the afternoon (after 12:00 PM).Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive anti-PD-1/PD-L1 immunotherapy either early in the day (before 11 AM) or late in the day (after 12 PM) based on randomization
Follow-up
Participants are monitored for safety, progression-free survival, and overall survival after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PD-1 Blocker
Trial Overview
The study investigates if the time of day when immunotherapy is administered affects its effectiveness. Patients are given a PD-1 blocker, which is a standard care immunotherapy, and are split into two groups based on treatment timing.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
NSCLC and solid tumor patients who receive first-line or ICI therapy early in the day (prior to 11AM) versus late in the day (after 12PM) and NSCLC patients with stable or response disease after induction therapy receiving maintenance ICI therapy early in the day (prior to 11AM) versus late in the day (after 12PM)
NSCLC and solid tumor patients who receive first-line or ICI therapy late in the day (started after 12 PM) and NSCLC patients with stable or response disease after induction therapy receiving maintenance ICI therapy late in the day (started after 12PM)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Liza Villaruz, MD
Lead Sponsor
Citations
Timing of first pembrolizumab infusion and long-term ...
We aimed to evaluate whether the timing of the first pembrolizumab infusion affects outcomes in unresectable non-small cell lung cancer (NSCLC).
Overall survival according to time-of-day of combined immuno ...
Early time-of-day administration (ToDA) of singe-agent ICIs has been associated with improved overall survival (OS) in patients with metastatic ...
A real-world study on the efficacy and safety of low-dose ...
Low-dose PD-1 monoclonal antibody therapy demonstrated comparable efficacy to standard-dose therapy with a lower incidence of severe irAEs in combination ...
Comparative efficacy and safety of first‑line PD‑1/PD‑L1 ...
PD-1/PD-L1 inhibitors, especially tislelizumab, pembrolizumab and nivolumab, were effective first-line treatments for NSCLC, providing survival benefits.
PD-1/PD-L1 Inhibitors for Non–Small Cell Lung Cancer
PD-1 and PD-L1 inhibitors reduce NSCLC growth and improve patient survival by preventing binding of PD-L1 ligands with PD-1 receptors expressed on tumor cells ...
A real-world study on the efficacy and safety of low-dose ...
Low-dose PD-1 monoclonal antibody therapy demonstrated comparable efficacy to standard-dose therapy with a lower incidence of severe irAEs in combination ...
Anti-PD-(L)1 therapy of non-small cell lung cancer–A ...
Anti-PD-(L)1 is a safe and an effective strategy in patients with advanced/metastatic NSCLC. Clinical responses to nivolumab and pembrolizumab, in particular, ...
Pembrolizumab versus Chemotherapy for PD-L1–Positive ...
The results of this randomized trial showed the superiority of anti–PD-1 therapy over platinum-based combination chemotherapy as first-line ...
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
Immune checkpoint blockade, especially blockade of programmed death-1 (PD-1) receptor and its ligand PD-L1, achieved robust responses and improved survival for ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.